CT‑based radiomics of bowel wall at baseline predicts the efficacy of Ustekinumab at week 16 in patients with Crohn's disease
{{output}}
Objectives: Ustekinumab is a biological treatment for Crohn's disease, but some patients do not respond. This study aimed to assess the role of radiomic techniques in predicting the treatment response by quantifying transmural i... ...
